vildagliptin and Glucose-Intolerance

vildagliptin has been researched along with Glucose-Intolerance* in 1 studies

Other Studies

1 other study(ies) available for vildagliptin and Glucose-Intolerance

Article	Year
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr Journal of medicinal chemistry, 2006, Oct-19, Volume: 49, Issue:21 Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (Ki(DPP)(-)(IV) = 1.0 nM) and selective (Ki(DPP8) > 30 microM; Ki(DPP9) > 30 microM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies. Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Binding Sites; Caco-2 Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Female; Glucose Intolerance; Glycoproteins; Humans; Hypoglycemic Agents; Macaca fascicularis; Models, Molecular; Molecular Structure; Pyridines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Stereoisomerism; Structure-Activity Relationship	2006

Article

Year

Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr

Journal of medicinal chemistry, 2006, Oct-19, Volume: 49, Issue:21

Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes. Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9. Further modification led to an extremely potent (Ki(DPP)(-)(IV) = 1.0 nM) and selective (Ki(DPP8) > 30 microM; Ki(DPP9) > 30 microM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies.

Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Binding Sites; Caco-2 Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Female; Glucose Intolerance; Glycoproteins; Humans; Hypoglycemic Agents; Macaca fascicularis; Models, Molecular; Molecular Structure; Pyridines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Stereoisomerism; Structure-Activity Relationship

2006